Preparation, physicochemical and biopharmaceutical characterization of oxcarbazepine-loaded nanostructured lipid carriers as potential antiepileptic devices

[1]  E. Fernandes,et al.  Organic Nanocarriers for Brain Drug Delivery , 2020 .

[2]  A. Talevi,et al.  Hybrid Ofloxacin/eugenol co-loaded solid lipid nanoparticles with enhanced and targetable antimicrobial properties. , 2019, International journal of pharmaceutics.

[3]  S. El-Gizawy,et al.  Formulation of acyclovir-loaded solid lipid nanoparticles: design, optimization, and in-vitro characterization , 2019, Pharmaceutical development and technology.

[4]  J. Prados,et al.  Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment , 2019, Nanomaterials.

[5]  M. Amaral,et al.  Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[6]  J. Sousa,et al.  Rethinking carbamazepine oral delivery using polymer‐lipid hybrid nanoparticles , 2019, International journal of pharmaceutics.

[7]  N. Damodharan,et al.  Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs , 2018, Future Journal of Pharmaceutical Sciences.

[8]  L. Casettari,et al.  A Tailored Thermosensitive PLGA-PEG-PLGA/Emulsomes Composite for Enhanced Oxcarbazepine Brain Delivery via the Nasal Route , 2018, Pharmaceutics.

[9]  L. Ferraro,et al.  Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[10]  M. Abdel-Bakky,et al.  Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation , 2018, International journal of pharmaceutics.

[11]  A. Dias,et al.  Lipid nanocarriers loaded with natural compounds: Potential new therapies for age related neurodegenerative diseases? , 2018, Progress in Neurobiology.

[12]  A. Talevi,et al.  Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: Physicochemical characterization and in vitro/in vivo evaluation. , 2018, Colloids and surfaces. B, Biointerfaces.

[13]  N. Durán,et al.  Development and tailoring of hybrid lipid nanocarriers. , 2018, Current pharmaceutical design.

[14]  Yangchao Luo,et al.  A novel and organic solvent-free preparation of solid lipid nanoparticles using natural biopolymers as emulsifier and stabilizer. , 2017, International journal of pharmaceutics.

[15]  A. Talevi,et al.  Interaction of Solid Lipid Nanoparticles and Specific Proteins of the Corona Studied by Surface Plasmon Resonance , 2017 .

[16]  Andrea V. Enrique,et al.  Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy. , 2017, Mini reviews in medicinal chemistry.

[17]  N. Mohallem,et al.  A comparison of TEM and DLS methods to characterize size distribution of ceramic nanoparticles , 2016 .

[18]  G. Awad,et al.  Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies. , 2016, International journal of pharmaceutics.

[19]  J. Xiong,et al.  Research Progress on the Role of ABC Transporters in the Drug Resistance Mechanism of Intractable Epilepsy , 2015, BioMed research international.

[20]  N. Denora,et al.  Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood–brain barrier and human placental trophoblast , 2015, International journal of nanomedicine.

[21]  Warren C W Chan,et al.  Nanoparticle-blood interactions: the implications on solid tumour targeting. , 2015, Chemical communications.

[22]  Nicholas A Peppas,et al.  Mathematical models in drug delivery: how modeling has shaped the way we design new drug delivery systems. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[23]  F. Cendes,et al.  The consequences of refractory epilepsy and its treatment , 2014, Epilepsy & Behavior.

[24]  G. Luna‐Bárcenas,et al.  Pharmacoresistant epilepsy and nanotechnology. , 2014, Frontiers in bioscience.

[25]  R. Amal,et al.  Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles. , 2014, Journal of materials chemistry. B.

[26]  H. Potschka,et al.  CNS transporters and drug delivery in epilepsy. , 2014, Current pharmaceutical design.

[27]  C. Drummond,et al.  Advances in drug delivery and medical imaging using colloidal lyotropic liquid crystalline dispersions. , 2013, Journal of colloid and interface science.

[28]  R. B. Walker,et al.  The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients , 2012, Pharmaceutical development and technology.

[29]  Donna A Volpe,et al.  Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. , 2011, Future medicinal chemistry.

[30]  P. Kwan,et al.  In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P‐glycoprotein , 2011, Epilepsia.

[31]  Surajit Das,et al.  Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery , 2011, AAPS PharmSciTech.

[32]  Shaofei Xie,et al.  DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles , 2010, The AAPS Journal.

[33]  A. Matzger,et al.  Crystal polymorphism in a carbamazepine derivative: oxcarbazepine. , 2010, Journal of pharmaceutical sciences.

[34]  Christian Bottomley,et al.  Estimation of the burden of active and life-time epilepsy: A meta-analytic approach , 2010, Epilepsia.

[35]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[36]  E. Smith,et al.  Experimental design for the optimization of lipid nanoparticles. , 2009, Journal of pharmaceutical sciences.

[37]  M. J. Santander-Ortega,et al.  Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. , 2006, Journal of colloid and interface science.

[38]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[39]  V. Venkateswarlu,et al.  Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[40]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  W Mehnert,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  S. Simões,et al.  Steric stabilization of nanoparticles: Size and surface properties , 1996 .

[44]  Nicholas A. Peppas,et al.  A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs , 1987 .

[45]  Alan Talevi,et al.  On the Development of New Antiepileptic Drugs for the Treatment of Pharmacoresistant Epilepsy: Different Approaches to Different Hypothesis , 2013 .

[46]  Heidrun Potschka,et al.  Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. , 2010, Pharmacology & therapeutics.

[47]  Balázs Sarkadi,et al.  The role of ABC transporters in drug resistance, metabolism and toxicity. , 2004, Current drug delivery.

[48]  T. May,et al.  Clinical Pharmacokinetics of Oxcarbazepine , 2003, Clinical pharmacokinetics.